Noveome Biotherapeutics Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cells

Source: Noveome Biotherapeutics

Noveome Biotherapeutics announced the publication of preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal of Neuro-Ophthalmology. These new results further support the neuroprotective properties of intranasally delivered ST266 in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON).

The publication entitled, “Effects of Varying Intranasal Treatment Regimens in ST266-Mediated Retinal Ganglion Cell Neuroprotection,” details the preclinical study exploring the neuroprotective effects of daily and twice daily intranasally delivered ST266 to evaluate different treatment regimens an EAE-induced experimental ON mouse model.

“In previous studies, we showed that a single daily dose of ST266 administered through the nose diminished visual dysfunction, prevented retinal ganglion cell loss, and reduced both inflammation and demyelination six weeks after induction of EAE,” Larry Brown, Sc.D., Noveome’s Chief Scientific Officer, said in a company news release.

Kenneth S. Shindler, MD, PhD, an associate professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania and Penn’s Scheie Eye Institute, and senior author on the paper continued, “In this study we demonstrated the ability of ST266 to confer longer-term neuroprotective effects, by showing that EAE mice that received either once or twice daily intranasal drops of ST266 starting from day 15 and repeated through day 56 showed significant preservation of vision, significant preservation of retinal ganglion cells, and significant reduction in optic nerve inflammation.”

“We are pleased to see these strong preclinical results that further validate this approach to non-cellular therapeutic treatment for optic nerve diseases. These results demonstrate the promise of our novel platform biologic, in which the multiple growth factors and anti-inflammatory cytokines present in ST266 are able to achieve neuroprotective benefits in varying intranasal treatment regimens,” said William J. Golden, Founder, Chairman and Chief Executive Officer of Noveome. “With this foundational science in hand, we look forward to further exploring ST266’s neuroprotective properties in our growing CNS pipeline with data from our Phase 1 clinical trial of intranasal ST266 in patients at risk of developing optic nerve disease expected later this year.”


Related Content